Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VISMODEGIB vs VONOPRAZAN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

VISMODEGIB vs VONOPRAZAN: Safety Overview

Metric VISMODEGIB VONOPRAZAN
Total FAERS Reports 8,135 2,019
Deaths Reported 864 73
Death Rate 10.6% 3.6%
Hospitalizations 974 342
Average Patient Age 69.6 yrs 63.6 yrs
% Female Patients 39.3% 65.3%
FDA Approval Date Jan 30, 2012 Nov 1, 2023
Manufacturer Genentech, Inc. Phathom Pharmaceuticals Inc.
Route ORAL ORAL
Marketing Status Prescription Prescription